Rhenman & Partners Asset Management AB cut its holdings in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) by 11.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 377,244 shares of the biopharmaceutical company’s stock after selling 50,398 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Sunesis Pharmaceuticals were worth $157,000 as of its most recent SEC filing.
SNSS has been the subject of several analyst reports. Zacks Investment Research downgraded Sunesis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 10th. ValuEngine downgraded Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 15th. Finally, HC Wainwright initiated coverage on Sunesis Pharmaceuticals in a research report on Thursday, December 20th. They issued a “neutral” rating and a $0.50 target price for the company. Five investment analysts have rated the stock with a hold rating, The stock presently has an average rating of “Hold” and a consensus price target of $1.67.
Shares of SNSS opened at $0.49 on Tuesday. The stock has a market capitalization of $18.34 million, a P/E ratio of -0.34 and a beta of 2.69. Sunesis Pharmaceuticals, Inc. has a one year low of $0.20 and a one year high of $7.69.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.
See Also: Earnings Per Share (EPS)
Want to see what other hedge funds are holding SNSS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS).
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.